Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Clinical trial NCT01381822 · UNKNOWN
Trial details
- NCT number
- NCT01381822
- Sponsor
- Threshold Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-01
- Primary completion
- 2014-06-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.